RxDoctor Payments Data

Stephen Tafor, MD

Interventional Pain Medicine · Macon, GANPI 1700844321

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,414 of the $16,082 with a category attached, or 71.0%. 29 manufacturers reported payments, led by Medtronic at 30.5% of the total. Reporting peaked in 2023 at $5,723 and has fallen 68.0% since, to $1,831 in 2025.

$16,082in general payments, 2019–2025

Across 376 payments — averaging $42.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$5K
  • Curonix LLC$2K
  • Nalu Medical, Inc.$976
  • Nevro Corp.$929
  • Surgentec$610
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$4,61629%
  • Food & beverage$11,41471%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,082 in reported general payments places this provider in the 85th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$292,917
Medicare patients
386
Services billed
3,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,370$61,507
BelbucaBuprenorphine Hcl67$45,898
Nucynta ErTapentadol Hcl26$31,279
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen639$19,203
OxycontinOxycodone Hcl26$18,153
Buprenorphine62$17,100
ZtlidoLidocaine16$10,289
Oxycodone Hcl323$6,845
Morphine Sulfate ErMorphine Sulfate151$4,203
Fentanyl43$4,045
Lidocaine15$1,978
Gabapentin121$1,261
Pregabalin53$1,143
Morphine Sulfate37$956
Tramadol Hcl ErTramadol Hcl13$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er$495$77,17793 claims
Scilex Pharmaceuticals Inc.Ztlido$203$10,28916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →